Moteur de recherche d’entreprises européennes
Financement de l’UE (3 874 497 €) : Un test de diagnostic pour améliorer la surveillance et la prise en charge des patients atteints de COVID-19 Hor21/10/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Un test de diagnostic pour améliorer la surveillance et la prise en charge des patients atteints de COVID-19
Coronavirus disease 2019 (COVID-19) caused by infection with SARS coronavirus 2 (SARS-CoV-2) has reached pandemic proportions with more than 7 million people infected and 0.4 million people killed worldwide. Death rates are accentuated by cardiovascular comorbidities and arrhythmias leading to unexpected major cardiovascular events. Being able to identify COVID-19 patients at risk of developing cardiovascular events leading to death would allow improving surveillance and care. Currently, there is no accurate method to predict outcome of COVID-19 patients. COVIRNA is a patient-centered Innovation Action aiming to satisfy this urgent and unmet need. COVIRNA will complete and deploy a prognostic system based on cardiovascular biomarkers of COVID-19 clinical outcomes combined with digital tools and artificial intelligence analytics (i.e. prediction model). Complementary expertise of 15 EU partners from the healthcare sector, academia, association and industry will allow conducting a large retrospective study on existing cohorts of COVID-19 patients. By upscaling the already validated and patented research use only FIMICS panel of cardiac-enriched long noncoding RNA biomarkers into an in-vitro diagnostic test (COVIRNA) adapted to COVID-19 patients, the project will quickly deliver a minimally-invasive, simple yet robust and affordable prognosis tool that can be used in the context of the current COVID-19 crisis as well as in further major health issues. By tackling the cardiovascular complications in COVID-19, known to contribute significantly to mortality, the project outputs are expected to have a major impact on the pandemic outcomes. The COVIRNA test will be CE-marked and prepared for commercialization, allowing to risk stratify patients, adapt therapies and to inform drug design.
| European Health Management Association | 151 625 € |
| Firalis | 1 109 588 € |
| Firalis Molecular Precision SA | 0,00 € |
| HEINRICH-HEINE-UNIVERSITAET DUESSELDORF | 50 000 € |
| Imperial College of Science Technology and Medicine | 400 000 € |
| Institut de Recerca de L'Hospital de La Santa Creu i Sant Pau Fundacion | 273 943 € |
| Institut Jozef Stefan | 50 000 € |
| Internacionalni Univerzitet U Sarajevu | 50 000 € |
| Luxembourg Institute OF Health | 699 822 € |
| PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG | 35 000 € |
| Policlinico SAN Donato S.p.A. | 174 388 € |
| The University of Edinburgh | 299 950 € |
| Universidade de Coimbra | 26 058 € |
| UNIVERSITAET LEIPZIG | 199 896 € |
| Universite Du Luxembourg | 199 604 € |
| UNIVERSITEIT MAASTRICHT | 154 625 € |
https://cordis.europa.eu/project/id/101016072
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.